BioSpace News Archive

Catalyst Pharmaceuticals, Inc. today announced that it will release third quarter 2018 financial results after market close on Wednesday, November 7, 2018.

Motif Bio plc announced today that the Company will participate in the following event

Karolinska Development announces today top line results from a Phase 2b study with tafoxiparin in treatment of protracted labor. The results show that the study did not achieve its primary endpoint of reducing the time to vaginal delivery through treatment with tafoxiparin. Karolinska Development will revalue the portfolio company’s book value, which is expected to negatively impact the result by SEK 40 million for the fourth quarter of 2018.

Epigenomics AG today announced the Veterans Administration - New York Harbor Healthcare System (VA-Manhattan) is commencing a study to assess the adherence impact of offering a blood-based colorectal cancer screening test and colonoscopy completion in patients who have refused colonoscopy and fecal immunochemical test (FIT).

Eight initiatives shortlisted from 33 initiatives presented by 24 government entities

Researchers at the University of Eastern Finland have developed novel antibacterial compounds, focusing on the role of LsrK kinase. LsrK kinase is a protein involved in bacterial communication.

MOR208 (L-MIND): Interim data from phase 2 L-MIND study of MOR208 plus lenalidomide in 81 patients with relapsed/refractory DLBCL accepted for oral presentation

Webinar transcription with key takeaways available on the National Nanotechnology Initiative website (https://bit.ly/2OgylYP)

Medigene AG today announced its participation at the following upcoming investor and scientific conferences:

New site to be located at LifeX™ Labs on city’s South Side